EA201590237A1 - Новые способы лечения антителами против her2 с низкой степенью фукозилирования - Google Patents

Новые способы лечения антителами против her2 с низкой степенью фукозилирования

Info

Publication number
EA201590237A1
EA201590237A1 EA201590237A EA201590237A EA201590237A1 EA 201590237 A1 EA201590237 A1 EA 201590237A1 EA 201590237 A EA201590237 A EA 201590237A EA 201590237 A EA201590237 A EA 201590237A EA 201590237 A1 EA201590237 A1 EA 201590237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fuzozylation
low
against her2
new methods
antibody treatment
Prior art date
Application number
EA201590237A
Other languages
English (en)
Inventor
Штеффен Голетц
Антье Даниельчик
Original Assignee
Гликотоп Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гликотоп Гмбх filed Critical Гликотоп Гмбх
Publication of EA201590237A1 publication Critical patent/EA201590237A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к области лечения злокачественной опухоли с использованием противораковых антител. Обеспечивается медицинское применение антител против HER2 с улучшенными характеристиками гликозилирования, в частности пониженное фукозилирование, которые проявляют повышенную эффективность.
EA201590237A 2012-07-18 2013-07-18 Новые способы лечения антителами против her2 с низкой степенью фукозилирования EA201590237A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673201P 2012-07-18 2012-07-18
US201261673229P 2012-07-18 2012-07-18
US201261673216P 2012-07-18 2012-07-18
EP12197768 2012-12-18
PCT/EP2013/065189 WO2014013019A1 (en) 2012-07-18 2013-07-18 Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
EA201590237A1 true EA201590237A1 (ru) 2015-05-29

Family

ID=49948317

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590237A EA201590237A1 (ru) 2012-07-18 2013-07-18 Новые способы лечения антителами против her2 с низкой степенью фукозилирования

Country Status (16)

Country Link
US (1) US20150166664A1 (ru)
EP (1) EP2874658A1 (ru)
JP (1) JP2015528802A (ru)
KR (1) KR20150036710A (ru)
CN (1) CN104394887A (ru)
AU (1) AU2013291964B2 (ru)
BR (1) BR112014032169A2 (ru)
CA (1) CA2875486A1 (ru)
EA (1) EA201590237A1 (ru)
IL (1) IL236714A0 (ru)
MA (1) MA37961A1 (ru)
MX (1) MX2015000730A (ru)
NZ (1) NZ701974A (ru)
SG (1) SG11201407841YA (ru)
WO (1) WO2014013019A1 (ru)
ZA (1) ZA201408938B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92659B1 (en) * 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
JP2020512382A (ja) * 2017-03-29 2020-04-23 グリコトープ ゲーエムベーハー Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体
CN112566667B (zh) * 2018-06-15 2023-06-09 上海美雅珂生物技术有限责任公司 治疗癌症的方法和材料
WO2022022526A1 (zh) * 2020-07-28 2022-02-03 百奥泰生物制药股份有限公司 抗her2抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007170A (es) 1999-01-15 2002-07-30 Genentech Inc Variantes de polipeptidos con funcion efectora alterada.
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2412701A1 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
SG2013005590A (en) * 2003-01-22 2015-06-29 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005086875A2 (en) * 2004-03-11 2005-09-22 City Of Hope A humanized anti-cea t84.66 antibody and uses thereof
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2662226C (en) * 2006-09-10 2020-08-04 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
TR201804897T4 (tr) * 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells

Also Published As

Publication number Publication date
ZA201408938B (en) 2016-09-28
BR112014032169A2 (pt) 2017-08-01
CA2875486A1 (en) 2014-01-23
IL236714A0 (en) 2015-02-26
WO2014013019A1 (en) 2014-01-23
SG11201407841YA (en) 2015-02-27
KR20150036710A (ko) 2015-04-07
MX2015000730A (es) 2015-08-06
NZ701974A (en) 2018-03-23
EP2874658A1 (en) 2015-05-27
AU2013291964B2 (en) 2017-12-14
US20150166664A1 (en) 2015-06-18
JP2015528802A (ja) 2015-10-01
MA37961A1 (fr) 2016-06-30
AU2013291964A1 (en) 2015-02-05
CN104394887A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
EA201400178A1 (ru) Лечение рака молочной железы
TN2015000396A1 (en) Antibody drug conjugates
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
EA201790413A1 (ru) Антитела против tigit
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EA201400991A1 (ru) Комбинированная терапия с использованием антител к человеческому csf-1r и ее применения
EA201400579A1 (ru) Антитела к il-36r
EA201400875A1 (ru) Антитела к cd47 и способы их применения
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
TR201910959T4 (tr) Elektromanyetik radyasyonun insan irisine uygulanması.
MX2014014162A (es) Anticuerpos multiespecificos.
MX2015014773A (es) Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
MX2021008755A (es) Un anticuerpo anti-tau para usarse al tratar una tauopatia.
EA201201357A1 (ru) Антитела к cd40
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201401204A1 (ru) Антитела к il-23p19
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
BR112013024211A2 (pt) tratamento de tumores sólidos
UY34582A (es) Anticuerpos anti-cxcr3
CR20150153A (es) Tratamiento para artitris reumatoide
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
EA201490180A1 (ru) Антитела к erbb3 в комбинации с паклитакселом для лечения гинекологических злокачественных заболеваний
MX2015008117A (es) Anticuerpos anti-h7cr.
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma